-
3 days ago | 
pharmacytimes.com | Luke Halpern
mRNA-1083, a multicomponent vaccine designed to protect against seasonal influenza and SARS-CoV-2, was found to induce higher immune responses compared with recommended standard care influenza (standard and high dose) and COVID-19 vaccines against a variety of strains that can sicken patients with an acceptable safety and tolerability profile, according to results from a phase 3, randomized, observer-blinded trial (NCT06097273) published in the Journal of the American Medical Association.1,2...
-
6 days ago | 
managedhealthcareexecutive.com | Luke Halpern
May 9, 2025Supplements And Featured PublicationsConference Brief: Asembia’s AXS25 Summit: A Special Report on Specialty PharmacySpecialty drugs are increasingly entering general medicine. Experts at Asembia’s AXS Summit say the trend will put a premium on leveraging artificial intelligence, technology and cross-functional expertise to create more personalized, efficient patient support services.
-
6 days ago | 
neurologylive.com | Ditte Primdahl |Shailee Shah |Isabella Ciccone |Luke Halpern
WATCH TIME: 4 minutes“We want to treat their underlying cancer, but we also want to treat their paraneoplastic syndrome. So, figuring out that perfect balance there is going to be key.”Managing paraneoplastic neurologic syndromes (PNS) in the era of cancer immunotherapy can present unique challenges because of the interplay between oncologic treatments and immune-mediated neurological complications.
-
6 days ago | 
pharmacytimes.com | Luke Halpern
Patients with mixed hyperlipidemia are often prescribed statins to help lower their cholesterol. Statins help decrease levels of low-density lipoprotein cholesterol (LDL-C) circulating in the blood and constitute a safe and effective treatment option for these patients. However, many patients face barriers to statin use, including preconditions that prevent them from taking a statin or requiring another medication that has contraindications with statins.
-
6 days ago | 
neurologylive.com | Kara R. Melmed |Isabella Ciccone |Luke Halpern
WATCH TIME: 2 minutes "If we can find the patients who really are expanding early, those are the patients where we can start to tailor our care and start to give more precise and focused management of blood pressure, anticoagulation reversal, etc.” High blood pressure (BP) is recognized as a major modifiable risk factor for intracerebral hemorrhage (ICH) and has been associated with a greater likelihood of initial hemorrhage, poorer outcomes, and increased risk of recurrent stroke,...
-
1 week ago | 
neurologylive.com | Roy H. Hamilton |Isabella Ciccone |Luke Halpern
WATCH TIME: 3 minutes “There's a lot of exciting work coming out with respect to how neuromodulation is being informed by other advances in technology and in our understanding of the brain, and that's leading to a couple of different emerging advances that I think are going to be really important.” A growing body of research supports the role of noninvasive brain stimulation including transcranial magnetic stimulation and transcranial direct current stimulation in promoting neuroplasticity...
-
1 week ago | 
pharmacytimes.com | Luke Halpern
The Future of Pharmacy Care Coalition, which includes national organizations such as the American Pharmacists Association (APhA), American Society of Health-System Pharmacists (ASHP), and the National Association of Chain Drug Stores (NACDS), has issued an urgent letter to Congress requesting the passage of the Ensuring Community Access to Pharmacist Services (ECAPS) ACT.1 The bipartisan legislation, known as House Resolution (HR) 3164, would affirm that senior Medicare beneficiaries have...
-
1 week ago | 
patientcareonline.com | Luke Halpern
The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients. The FDA has granted regulatory approval to 12.5-mg chlorthalidone (HemiClor; PRM Pharma, LLC) tablets, indicated for the lowering of blood pressure in adults with hypertension, according to a news release by PRM Pharma.
-
1 week ago | 
pharmacytimes.com | Luke Halpern
As the landscape of glucagon-like peptide 1 receptor agonists (GLP-1) continues to evolve across health care, opportunities and challenges present themselves for patients, providers, and payers, according to Becky Davis, principal of Charles River Associates, at her session “GLP-1s: Riding the Wave of Innovative Medications” presented during Asembia’s AXS25 Summit.
-
1 week ago | 
pharmacytimes.com | Luke Halpern
Constraint-induced cognitive therapy (CICT), which combines behavior change techniques with speed of processing training, was found to improve brain fog and other symptoms associated with long COVID while allowing many afflicted patients to return to work, according to the results of a randomized controlled trial (RCT) published in Rehabilitation Psychology.1 CICT, which is a modification of constraint-induced movement therapy, is used to aid in the rehabilitation of patients following stroke...
